切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2018, Vol. 07 ›› Issue (01) : 16 -20. doi: 10.3877/cma.j.issn.2095-3224.2018.01.004

所属专题: 文献

专家论坛

结直肠癌腹膜转移治疗策略——AJCC第八版分期的启示
宋纯1,(), 张顺1   
  1. 1. 200120 上海市东方医院(同济大学附属东方医院)胃肠肛肠外科
  • 收稿日期:2017-04-27 出版日期:2018-02-25
  • 通信作者: 宋纯

Current treatment options for colorectal cancer peritoneal carcinomatosis——the inspiration from the 8th edition of AJCC cancer staging system

Chun Song1,(), Shun Zhang1   

  1. 1. Department of Gastrointestinal Surgery, Shanghai East Hospital (East Hospital Affiliated to Tongji University), Shanghai 200120, China
  • Received:2017-04-27 Published:2018-02-25
  • Corresponding author: Chun Song
  • About author:
    Corresponding author: Song Chun, Email:
引用本文:

宋纯, 张顺. 结直肠癌腹膜转移治疗策略——AJCC第八版分期的启示[J/OL]. 中华结直肠疾病电子杂志, 2018, 07(01): 16-20.

Chun Song, Shun Zhang. Current treatment options for colorectal cancer peritoneal carcinomatosis——the inspiration from the 8th edition of AJCC cancer staging system[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(01): 16-20.

结直肠癌腹膜转移发生率较高且预后差。美国癌症联合委员会(AJCC)第八版癌症分期系统进一步更新远处转移(M)的分期,新增M1c期,即结直肠癌腹膜转移。重视腹膜转移的诊治在我国有着重要作用。近年来,对结直肠癌腹膜转移的机制及治疗等认识程度不断增加,对其治疗效果也有了很大的提高。本文我们将探讨结直肠癌腹膜转移的治疗策略。

Peritoneum is one of the common site of colorectal cancer metastasis and associated with a poor prognosis. The 8 th edition of AJCC cancer staging system has updated the M staging. Peritoneal carcinomatosis metastasis to visceral organs is designated as M1c. It is important to pay attention to the peritoneal metastasis which takes heavy burden on healthy cost. Great progress has been made in the area of the clinical presentation and mechanisms of disease progression. The aim of our study is to provide the current status of the diagnosis and treatment of peritoneal carcinomatosis.

表1 Sugarbaker细胞减灭术完全性分级表
[1]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2]
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[3]
Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study [J]. Int J Cancer, 2011, 128(11): 2717-2725.
[4]
Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer [J]. Br J Surg, 2012, 99(5): 699-705.
[5]
Aoyagi T, Terracina KP, Raza A, et al. Current treatment options for colon cancer peritoneal carcinomatosis [J]. World J Gastroenterol, 2014, 20(35): 12493-12500.
[6]
Mo S, Cai G. Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature [J]. Gastroenterol Res Pract, 2016, 2016: 1516259.
[7]
Amin Mahul B., Edge Stephen B., Frederick L, et al. AJCC Cancer Staging Manual[S]. Springer, 2017.
[8]
姚宏伟,吴鸿伟,刘荫华. 从传统"群体化"诊治到精准"个体化"医疗:AJCC第八版结直肠癌分期系统更新解读 [J]. 中华外科杂志, 2017, 55(1): 24-27.
[9]
Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841 [J]. J Clin Oncol, 2012, 30(3): 263-267.
[10]
孙立峰,童舟,丁克峰. 外科肿瘤细胞减灭术联合腹腔内热灌注化疗--结直肠癌腹膜转移治疗的突破方向? [J]. 中华结直肠疾病电子杂志 2015, 4(1): 11-16.
[11]
Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer [J]. Int J Clin Oncol, 2012, 17(1): 1-29.
[12]
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis [J]. Cancer Treat Res, 1996, 82: 359-374.
[13]
Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? [J]. Ann Surg, 2013, 257(6): 1065-1071.
[14]
Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1, 013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis [J]. Ann Surg Oncol, 2014, 21(13): 4195-4201.
[15]
李雁,周云峰,梁寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识 [J]. 中国肿瘤临床, 2015, 42(4): 198-206.
[16]
Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy [J]. Oncologist, 2005, 10(2): 112-122.
[17]
Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures [J]. Ann Surg Oncol, 2003, 10(2): 863-869.
[18]
Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States [J]. Ann Surg Oncol, 2014, 21(5): 1501-1505.
[19]
Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin [J]. J Clin Oncol, 2009, 27(5): 681-685.
[20]
Ihemelandu CU, Shen P, Stewart JH, et al. Management of peritoneal carcinomatosis from colorectal cancer [J]. Semin Oncol, 2011, 38(4): 568-575.
[21]
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer [J]. J Clin Oncol, 2003, 21(20): 3737-3743.
[22]
Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer [J]. Ann Surg Oncol, 2008, 15(9): 2426-2432.
[23]
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer [J]. Ann Oncol, 2016, 27(8): 1386-1422.
[24]
Klaver CE, Groenen H, Morton DG, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines [J]. Colorectal Dis, 2017, 19(3): 224-236.
[25]
Sammartino P, Sibio S, Biacchi D, et al. Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC [J]. Gastroenterol Res Pract, 2012, 2012: 141585.
[26]
Baratti D, Kusamura S, Iusco D, et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases [J]. Ann Surg Oncol, 2017, 24(1): 167-175.
[27]
王展怀,孙立峰,袁瑛, 等. 腹膜转移的结肠癌患者MDT诊治二例 [J]. 中华结直肠疾病电子杂志 , 2016, 5(4): 351-354.
[28]
Sugarbaker PH. Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer [J]. World J Gastroenterol, 2014, 20(28): 9286-9291.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[7] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[8] 袁园园, 岳乐淇, 张华兴, 武艳, 李全海. 间充质干细胞在呼吸系统疾病模型中肺组织分布及治疗机制的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 374-381.
[9] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[10] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[11] 国文凯, 纪鹏程, 毕靖茹, 谢院生. IgA 肾病的十种治疗措施[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 327-333.
[12] 帖璇, 苏晓乐, 王利华. 抗中性粒细胞胞质抗体相关性血管炎治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 345-351.
[13] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?